Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Greenbank Capital | OTC Markets | Financial | Investment Banking & Investment Services | US$1.35M | -0.3x | 0.92 | US$0.010 | -50% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Heliogen | OTC Markets | Energy | Renewable Energy | US$17.78M | -0.1x | 0 | US$2.96 | -7.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1,213.6% Upside | Upgrade to Pro+ | |
C4 | NASDAQ | Healthcare | Biotechnology & Medical Research | US$462.37M | -2.8x | -0.26 | US$6.68 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 71.6% Upside | Upgrade to Pro+ | |
Digicann Ventures | OTC Markets | Healthcare | Healthcare Providers & Services | US$159K | 0x | 0 | US$0.02 | 110.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ryvyl | NASDAQ | Technology | Software & IT Services | US$12.49M | -0.2x | 0.01 | US$1.94 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Plus Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$10.35M | -0.6x | -0.01 | US$1.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1,066.7% Upside | Upgrade to Pro+ | |
Esperion | NASDAQ | Healthcare | Pharmaceuticals | US$413.02M | -3.1x | -0.07 | US$2.18 | -5.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 246.3% Upside | Upgrade to Pro+ | |
Eiger Biopharma | OTC Markets | Healthcare | Biotechnology & Medical Research | US$20.73M | -0.3x | -0.01 | US$14 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 114.3% Upside | Upgrade to Pro+ | |
Babcock Wilcox Enterprises | NYSE | Industrials | Machinery, Tools, Heavy Vehicles, Trains & Ships | US$122.87M | -1x | 0 | US$13.97 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Mustang Bio | NASDAQ | Healthcare | Biotechnology & Medical Research | US$11.51M | -0.1x | -0.01 | US$0.33 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 498.8% Upside | Upgrade to Pro+ | |
2Seventy Bio | NASDAQ | Healthcare | Biotechnology & Medical Research | US$242.63M | -0.9x | -0.06 | US$4.28 | -9.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 69.5% Upside | Upgrade to Pro+ | |
Solid Biosciences | NASDAQ | Healthcare | Biotechnology & Medical Research | US$326.23M | -2.3x | -0.07 | US$8.64 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 90.6% Upside | Upgrade to Pro+ | |
Redfin | NASDAQ | Real Estate | Real Estate Operations | US$887.67M | -6.2x | -0.13 | US$7.43 | -8.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -7.9% Downside | Upgrade to Pro+ | |
Lemonade | NYSE | Financial | Insurance | US$1.22B | -5.8x | -0.27 | US$17.30 | -4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -11.3% Downside | Upgrade to Pro+ | |
HomeStreet | NASDAQ | Financial | Banking Services | US$267.59M | -17.8x | 0.04 | US$14.20 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2.4% Upside | Upgrade to Pro+ | |
Qurate Retail B | NASDAQ | Consumer Cyclicals | Diversified Retail | US$1.58B | -1.6x | -0.02 | US$3.92 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Oblong | NASDAQ | Technology | Electronic Equipment & Parts | US$5.03M | -0.3x | -0.01 | US$0.18 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Autolus Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$1.20B | -3.7x | -0.61 | US$4.51 | -3.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 134.5% Upside | Upgrade to Pro+ | |
Aura Biosciences | NASDAQ | Healthcare | Biotechnology & Medical Research | US$505.84M | -4x | -1.01 | US$9.86 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 95.9% Upside | Upgrade to Pro+ | |
Emergent Biosolutions | NYSE | Healthcare | Pharmaceuticals | US$545.50M | -0.9x | 0.03 | US$10.57 | -16.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -37.1% Downside | Upgrade to Pro+ | |
Upland Software Inc | NASDAQ | Technology | Software & IT Services | US$62.91M | -0.5x | -0.02 | US$2.31 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.5% Upside | Upgrade to Pro+ | |
Fangdd Network | NASDAQ | Real Estate | Real Estate Operations | US$2.53M | -0.1x | -0 | US$0.39 | -7.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Design Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | US$285.30M | -4.8x | -0.32 | US$5.05 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -21.6% Downside | Upgrade to Pro+ | |
Koss | NASDAQ | Technology | Computers, Phones & Household Electronics | US$84.03M | -74.6x | 0.69 | US$9.11 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
MeiraGTx | NASDAQ | Healthcare | Biotechnology & Medical Research | US$311.89M | -3.9x | -0.08 | US$4.88 | -6.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 148.6% Upside | Upgrade to Pro+ | |
Eos Energy Enterprises | NASDAQ | Industrials | Machinery, Tools, Heavy Vehicles, Trains & Ships | US$392.93M | -1.4x | -0.03 | US$1.82 | -7.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 77.7% Upside | Upgrade to Pro+ | |
Phreesia | NYSE | Technology | Software & IT Services | US$1.41B | -11.3x | -0.4 | US$24.61 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.2% Upside | Upgrade to Pro+ | |
Altimmune | NASDAQ | Healthcare | Biotechnology & Medical Research | US$431.79M | -3.8x | -0.51 | US$6.09 | -4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 277.4% Upside | Upgrade to Pro+ | |
BioLife Solutions | NASDAQ | Healthcare | Healthcare Equipment & Supplies | US$1.07B | -16.2x | -0.3 | US$23.36 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.2% Upside | Upgrade to Pro+ | |
Hovnanian Enterprises | NYSE | Consumer Cyclicals | Homebuilding & Construction Supplies | US$1.18B | 6.2x | 0.37 | US$198.24 | -5.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |